• 提示：詳情請下載說明書。

• 產(chǎn)品描述： Cisapride (R 51619) is an orally active 5-HT4 receptor agonist with an EC50 value of 140 nM. Cisapride is a hERG blocker with an IC50 value of 9.4 nM. Cisapride is a gastroprokinetic agent that stimulates gastrointestinal motor activity

• 靶點： 5-HT4 Receptor:0.14 μM (EC50);PotassiumChannel;5-HTReceptor;HER

• 體內(nèi)研究：
  Cisapride (0.1-1 mg/kg；靜脈注射，一次) 刺激清醒犬的胃竇和結(jié)腸運(yùn)動。Cisapride (2 mg/kg，(腹腔注射)；4 mg/kg，(口服)；一次) 與三硝基苯磺酸處理的大鼠在宏觀特征、組織病理學(xué)特征、細(xì)胞因子譜和體重變化均無顯著差異。

• 參考文獻(xiàn)：
  1. Toga, T., Y. Kohmura, and R. Kawatsu, The 5-HT(4) agonists cisapride, mosapride, and CJ-033466, a Novel potent compound, exhibit different human ether-a-go-go-related gene (hERG)-blocking activities. J Pharmacol Sci, 2007. 105(2): p. 207-10. 2. Sung, K.W. and S.J. Hahn, Effect of mosapride on Kv4.3 potassium channels expressed in CHO cells. Naunyn Schmiedebergs Arch Pharmacol, 2013. 386(10): p. 905-16. 3. Mine, Y, et al. Comparison of effect of mosapride citrate and existing 5-HT4 receptor agonists on gastrointestinal motility in vivo and in vitro. J Pharmacol Exp Ther, 1997. 283(3): p. 1000-8. 4. Motavallian, A, et al., Does Cisapride, as a 5HT(4) Receptor Agonist, Aggravate the Severity of TNBS-Induced Colitis in Rat. Gastroenterol Res Pract, 2012. 2012: p. 362536.

• 溶解性： DMSO  :  100  mg/mL  (214.62  mM;  Need  ultrasonic)    H2O  :  0.1  mg/mL  (0.21  mM;  Need  ultrasonic  and  warming)

• 保存條件： -20℃

• 配置溶液濃度參考：
  

  	1mg	5mg	10mg
  1 mM	2.146 ml	10.731 ml	21.462 ml
  5 mM	0.429 ml	2.146 ml	4.292 ml
  10 mM	0.215 ml	1.073 ml	2.146 ml
  50 mM	0.043 ml	0.215 ml	0.429 ml

• 注意：部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。

輸入產(chǎn)品批號：

本計算器可幫助您計算出特定溶液中溶質(zhì)的質(zhì)量、溶液濃度和體積之間的關(guān)系，公式為：

質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)

• pg ng μg mg g kg =
  fM pM nM μM mM M *
  nL μL mL L *